DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.

Analysts predict sales of Dato-DXd could hit $5.9 billion in 2030, but the antibody-drug conjugate faced a series of setbacks ...

AstraZeneca's Datroway gains FDA approval for HR-positive, HER2-negative breast cancer after prior therapies, based on Phase ...

Four of the top 10 drugs by prescription sales in 2025 will be from the new incretin class, according to the latest analysis by Evaluate. Consensus forecasts for Ozempic, Wegovy, Mounjaro and Zepbound ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

As more Asia biotechs turn to regenerative medicine to address disorders without a cure, Medipost Inc. is continuing global expansion with Cartistem, its allogeneic human umbilical cord blood-derived ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...